ReScript 12.0 has launched, marking a milestone in modernizing the language with a rewritten build system, improved ...

Retrieval-augmented generation breaks at scale because organizations treat it like an LLM feature rather than a platform ...

A new sample of the ToneShell backdoor, typically seen in Chinese cyberespionage campaigns, has been delivered through a kernel-mode loader in attacks against government organizations.

The leaked internal chat communications of the Black Basta ransomware group offer an unprecedented view into how cybercriminals operate, plan attacks, and ...

If 2023 was the year of shock and 2024 was the year of experimentation, 2025 marks the moment the corporate world finally accepted that artificial intelligence is not just a novelty—it is the new ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Multiple factors contribute to a positive patient experience, says the new CMO of AdventHealth Altamonte Springs. They include effective communication with patients, the hospital environment, food ...

President Trump rated his highly anticipated sit down with Chinese leader Xi Jinping a 12 out of 10. WSJ’s Alexander Ward explains why. Photo: Yonhap/EPA/Shutterstock In an unusual diplomatic move, ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...